Skip to main content
Premium Trial:

Request an Annual Quote

RareCyte CyteFinder II and CyteFinder II HT

RareCyte is introducing its CyteFinder II and CyteFinder II HT instruments, next-generation versions of the company's CyteFinder instruments for multi-omic liquid biopsy and tissue research in clinical labs. Both instruments perform rapid, whole-slide imaging in seven fluorescence channels as well as brightfield for immunofluorescence, immunohistochemistry, and H&E.

CyteFinder II offers researchers a complete workflow in a single platform for imaging through cell retrieval of both liquid biopsy and tissue samples. The integrated CytePicker Retrieval Module enables discovery research by providing image-guided cell retrieval for high-depth sequencing. This workflow can be used for circulating tumor cell mutational analysis, RNA-based T-cell receptor discovery, and differential expression analysis of tissue microenvironments.

CyteFinder II HT meets the demand of high-volume pathology and liquid biopsy labs with hands-free, rapid, whole-slide scanning of up to 80 slides and a barcode-driven workflow for sample tracking. The machine learning-driven workflow for rare cell detection and automated tissue finding make CyteFinder II HT ideal for clinical researchers performing either cellular or tissue-based multiplexed analysis.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.